AtriCure: Atrial fibrillation trial to be ‘inflection point’ for business
The launch of a pivotal clinical trial next year for a “hybrid” procedure to treat atrial fibrillation patients will be an “inflection point” for cardiac surgical device maker AtriCure’s (NASDAQ:ATRC) U.S. business, its CEO said. The pivotal clinical trial, which could lead to regulatory approval of the hybrid procedure to treat atrial fibrillation and is […]